Combination therapies that stimulate antitumor immunity promote immune-mediated bystander killing of KRAS-G12C inhibitor resistant subpopulations, providing a strategy to overcome drug resistance that...

The 2026 #PhD recruitment at The Francis Crick Institute is now open! We are please to announce an additional opportunity to join our laboratory through a PhD project in collaboration with the Rocio...

The EACR Scientific Officer, Alexandra Boitor, summarises the recent virtaul conference 'EACR Drugging and Regulating the MAP Kinase Pathway'.

GDP-bound form of KRASG12C inhibitors have been approved for the treatment of patients with advanced KRASG12C mutant non-small cell lung cancer (NSCLC), however resistance to these drugs is often obse...